Literature DB >> 16958134

Metric attributes of the unified Parkinson's disease rating scale 3.0 battery: part II, construct and content validity.

Maria João Forjaz1, Pablo Martinez-Martin.   

Abstract

This article is the second of a two-part series concerning the metric properties of the following three Parkinson's disease (PD) scales: modified Hoehn and Yahr staging (H&amp;Y), Schwab and England (S&amp;E), and Unified Parkinson's Disease Rating Scale (UPDRS) 3.0. Part II focuses on construct and content validity. To assess construct validity, a sample of 1,136 PD patients completed the above-mentioned PD scales. Correlation coefficients between measures of disability and dysfunction [S&amp;E, UPDRS Activities of Daily Living (ADL), and UPDRS Motor Examination] were |r| = 0.69-0.77, indicating good convergent validity. Results showed that the S&amp;E (F(5,945) = 193.47; P < 0.0001) and UPDRS subscales discriminated between modified H&amp;Y stages (F(20,2784) = 25.28; P < 0.001). A panel of 12 to 13 international experts rated the relevance of the scales and items. This enabled the scales' content validity index to be calculated, which ranged from 41.7% (UPDRS Mentation) to 83.3% (UPDRS Motor Examination). In conclusion, while the modified H&amp;Y, S&amp;E, and UPDRS displayed satisfactory construct validity, the content validity of all scales except UPDRS Motor Examination failed to attain adequate standards.

Entities:  

Mesh:

Year:  2006        PMID: 16958134     DOI: 10.1002/mds.21071

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  8 in total

1.  Psychometric Properties of Activity, Self-Efficacy, and Quality-of-Life Measures in Individuals with Parkinson Disease.

Authors:  Vanina Dal Bello-Haas; Laura Klassen; M Suzanne Sheppard; Amy Metcalfe
Journal:  Physiother Can       Date:  2011-01-20       Impact factor: 1.037

2.  Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS).

Authors:  Pablo Martinez-Martin; Carmen Rodriguez-Blazquez; Mario Alvarez-Sanchez; Tomoko Arakaki; Alberto Bergareche-Yarza; Anabel Chade; Nelida Garretto; Oscar Gershanik; Monica M Kurtis; Juan Carlos Martinez-Castrillo; Amelia Mendoza-Rodriguez; Henry P Moore; Mayela Rodriguez-Violante; Carlos Singer; Barbara C Tilley; Jing Huang; Glenn T Stebbins; Christopher G Goetz
Journal:  J Neurol       Date:  2012-08-05       Impact factor: 4.849

3.  Dopamine replacement therapy does not restore the ability of Parkinsonian patients to make rapid adjustments in motor strategies according to changing sensorimotor contexts.

Authors:  E Tunik; A G Feldman; H Poizner
Journal:  Parkinsonism Relat Disord       Date:  2007-04-18       Impact factor: 4.891

4.  Development and validation of prognostic survival models in newly diagnosed Parkinson's disease.

Authors:  Angus D Macleod; Ingvild Dalen; Ole-Bjørn Tysnes; Jan Petter Larsen; Carl E Counsell
Journal:  Mov Disord       Date:  2017-10-04       Impact factor: 10.338

5.  Choreographing life-experiences of balance control in people with Parkinson's disease.

Authors:  Sofie LaGrone; Conran Joseph; Hanna Johansson; Birgit Enberg; Erika Franzén
Journal:  BMC Neurol       Date:  2020-02-10       Impact factor: 2.474

6.  Measurement tools to assess activities of daily living in patients with Parkinson's disease: A systematic review.

Authors:  Raquel Bouça-Machado; Adriana Fernandes; Carlo Ranzato; Duane Beneby; Hipólito Nzwalo; Joaquim J Ferreira
Journal:  Front Neurosci       Date:  2022-07-20       Impact factor: 5.152

7.  Dementia and functional decline in patients with Parkinson's disease.

Authors:  Florindo Stella; Claudio Eduardo Muller Banzato; Elizabeth Maria Aparecida Barasnevicius Quagliato; Maura Aparecida Viana; Gustavo Christofoletti
Journal:  Dement Neuropsychol       Date:  2008 Apr-Jun

8.  Predictors of functional dependency in Parkinson's disease.

Authors:  Angus D Macleod; Carl E Counsell
Journal:  Mov Disord       Date:  2016-10       Impact factor: 10.338

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.